20:23 , Nov 3, 2017 |  BC Week In Review  |  Financial News

Allena raises $74.7M IPO

On Nov. 1, kidney disease company Allena Pharmaceuticals Inc. (NASDAQ:ALNA) raised $74.7 million through the sale of 5.3 million shares at $14 in an IPO underwritten by Credit Suisse, Jefferies, Cowen and Wedbush PacGrow. The...
15:10 , Nov 2, 2017 |  BC Extra  |  Financial News

Allena slips after pricing $74.7M IPO

Allena Pharmaceuticals Inc. (NASDAQ:ALNA) dipped $4.02 (29%) to $9.98 on Thursday after it raised $74.7 million through the sale of 5.3 million shares at $14 in an IPO underwritten by Credit Suisse, Jefferies, Cowen and...
19:51 , Oct 13, 2017 |  BC Week In Review  |  Financial News

Allena proposes $92M IPO

Kidney disease company Allena Pharmaceuticals Inc. (Newton, Mass.) proposed to raise up to $92 million on Oct. 6 in an IPO on NASDAQ underwritten by Credit Suisse, Jefferies, Wedbush and Cowen. Allena's lead candidate, ALLN-177...
19:53 , Oct 9, 2017 |  BC Extra  |  Financial News

Allena proposes $92M IPO

Kidney disease company Allena Pharmaceuticals Inc. (Newton, Mass.) proposed to raise up to $92 million in an IPO on NASDAQ underwritten by Credit Suisse, Jefferies, Wedbush and Cowen. Allena's lead candidate, ALLN-177 , is an...
08:00 , Feb 15, 2016 |  BC Week In Review  |  Clinical News

ALLN-177: Phase II started

Allena began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 7,500 units of oral ALLN-177 thrice daily with meals for 28 days in about 44 patients. Allena Pharmaceuticals Inc. , Newton, Mass.   Product:...
02:35 , Dec 10, 2015 |  BC Extra  |  Financial News

Allena's series C round brings $53M

Allena Pharmaceuticals Inc. (Newton, Mass.) raised $53 million in a series C financing led by Partner Fund Management. New investors Fidelity and Wellington Management also participated, along with existing investors Frazier Healthcare, HBM BioCapital and...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Clinical News

ALLN-177: Phase IIb started

Allena began a double-blind, placebo-controlled, crossover, U.S. Phase IIb trial to evaluate 1,500, 3,000 and 7,500 units/meal oral ALLN-177 thrice daily in up to 60 patients. Allena Pharmaceuticals Inc. , Newton, Mass.   Product: ALLN-177...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Clinical News

ALLN-177: Phase IIa data

An open-label, U.S. Phase IIa trial in 16 patients with recurring kidney stones and enteric or idiopathic hyperoxaluria showed that oral ALLN-177 given up to 3 times daily with meals for 4 days led to...
02:09 , Dec 5, 2014 |  BC Extra  |  Financial News

HBM joins Allena syndicate in $25M series B

Allena Pharmaceuticals Inc. (Newton, Mass.) raised $25 million in a series B financing led by HBM Partners. Existing investors Frazier Healthcare; Third Rock Ventures; Bessemer Venture Partners; and new investor Pharmstandard International participated. HBM's Axel...
07:00 , May 12, 2014 |  BC Week In Review  |  Clinical News

ALLN-177: Phase I data

A double-blind, crossover Phase I trial in 30 healthy volunteers who were placed on a high oxalate diet and showed a sustained increase in urinary oxalate levels that was consistent with hyperoxaluria showed that oral...